{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T05:21:37Z","timestamp":1762752097697,"version":"build-2065373602"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Biliary tract malignancies are highly lethal, with a 5-year overall survival (OS) rate of less than 10%. This report describes a patient with HER2-positive advanced gallbladder cancer who achieved an OS of 90 months through multidisciplinary interventions and anti-HER2 targeted therapy. The patient achieved a prolonged period of disease stability, who was treated with various anti-HER2 targeted therapy, such as trastuzumab combined with pyrotinib and HER2-targeted antibody-drug conjugate (ADC). The patient received multiple local treatments (e.g., surgery, cryoablation, CyberKnife, and particle implantation) to further control the disease progression. Dynamic CA199 levels paralleled the treatment efficacy. This report underscores the significance of molecular profiling-guided personalized therapy and integrated multidisciplinary management in the treatment of biliary tract cancers.<\/jats:p>","DOI":"10.3389\/fonc.2025.1669818","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T05:18:40Z","timestamp":1762751920000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["HER2-targeted therapy combined with multidisciplinary management in advanced gallbladder cancer: a case report with 90-month survival"],"prefix":"10.3389","volume":"15","author":[{"given":"Yulin","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangwei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shize","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinglei","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-011-1134-3","article-title":"Incidental gallbladder cancer by the AFC-GBC-2009 Study Group","volume":"35","author":"Fuks","year":"2011","journal-title":"World J Surg"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2012.682628","article-title":"Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma","volume":"51","author":"Kang","year":"2012","journal-title":"Acta Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"114000","DOI":"10.1016\/j.ejca.2024.114000","article-title":"Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)","volume":"202","author":"Roth","year":"2024","journal-title":"Eur J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02010","article-title":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): A multicenter, single-arm, phase II trial","volume":"42","author":"Ohba","year":"2024","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4091","article-title":"Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study [abstract","volume":"42","author":"Pant","year":"2024","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-panTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"114199","DOI":"10.1016\/j.ejca.2024.114199","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population","volume":"208","author":"Rimini","year":"2024","journal-title":"Eur J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.08.017","article-title":"Worldwide burden of and trends in mortality from gallbladder and other biliary tract cancers","volume":"16","author":"Torre","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract Malignancies; systematic review and meta-analysis: a potential therapeutic target","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02078","article-title":"Pertuzumab plus trastuzumab in patients with biliary tract cancer with ERBB2\/3 alterations: results from the targeted agent and profiling utilization registry study","volume":"42","author":"Cannon","year":"2024","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): A phase II basket study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S232912","article-title":"Identification of an activating mutation in the extracellular domain of HER2 conferring resistance to pertuzumab","volume":"12","author":"Zhang","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000038508","article-title":"HER2\/PI3K\/AKT pathway in HER2-positive breast cancer: A review","volume":"103","author":"Pan","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk134","article-title":"Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer","volume":"99","author":"Scaltriti","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.335","article-title":"Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer","volume":"107","author":"Minuti","year":"2012","journal-title":"Br J Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1158\/2159-8290.CD-18-0598","article-title":"EGFR and MET amplifications determine response to HER2 inhibition in ERBB2-amplified esophagogastric cancer","volume":"9","author":"Sanchez-Vega","year":"2019","journal-title":"Cancer Discov"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2024.02.03","article-title":"Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors","volume":"36","author":"Zhang","year":"2024","journal-title":"Chin J Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"188847","DOI":"10.1016\/j.bbcan.2022.188847","article-title":"Predictive and prognostic value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors: A systematic review and meta-analysis","volume":"1878","author":"Shi","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000366426","article-title":"PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer","volume":"88","author":"Zhang","year":"2015","journal-title":"Oncology"},{"key":"B26","article-title":"The role of p95HER2 in trastuzumab resistance in breast cancer","volume":"21","author":"Ozkavruk Eliyatkin","year":"2016","journal-title":"J BUON"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911498","article-title":"HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies","volume":"12","author":"Gandullo-S\u00e1nchez","year":"2020","journal-title":"EMBO Mol Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e3182569189","article-title":"Stereotactic body radiotherapy in the treatment of adrenal metastases","volume":"36","author":"Ahmed","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.21037\/cco.2017.06.30","article-title":"Stereotactic body radiotherapy for primary renal cell carcinoma and adrenal metastases","volume":"6","author":"Kothari","year":"2017","journal-title":"Chin Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.adro.2018.11.007","article-title":"Initial results of a prospective study of adjuvant pancreatic stereotactic body radiation therapy for close or positive margins","volume":"4","author":"Bernard","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"20200645","DOI":"10.1259\/bjr.20200645","article-title":"Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients","volume":"93","author":"Arcidiacono","year":"2020","journal-title":"Br J Radiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00345-024-05140-9","article-title":"Stereotactic Body Radiotherapy: is less fractionation more effective in adrenal and renal Malignant lesions","volume":"42","author":"Rivas","year":"2024","journal-title":"World J Urol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-03943-0","article-title":"Robotic stereotactic body radiotherapy for the management of adrenal gland metastases: a bi-institutional analysis","volume":"149","author":"Ehret","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ijrobp.2020.01.017","article-title":"Stereotactic body radiation therapy of adrenal metastases: A pooled meta-analysis and systematic review of 39 studies with 1006 patients","volume":"107","author":"Chen","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B35","doi-asserted-by":"publisher","first-page":"7836","DOI":"10.1038\/s41598-020-64770-2","article-title":"Clinical efficacy of Stereotactic Body Radiation Therapy (SBRT) for adrenal gland metastases: A multi-center retrospective study from China","volume":"10","author":"Zhao","year":"2020","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris","year":"2024","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00520-023-08083-w","article-title":"Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data","volume":"31","author":"Guven","year":"2023","journal-title":"Support Care Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03366-x","article-title":"Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study","volume":"72","author":"Rizzo","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2021.2029405","article-title":"Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study","volume":"17","author":"Rizzo","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1669818\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T05:18:41Z","timestamp":1762751921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1669818\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":39,"alternative-id":["10.3389\/fonc.2025.1669818"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1669818","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"article-number":"1669818"}}